HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

riociguat

structure in first source
Also Known As:
BAY 63-2521; BAY-63-2521
Networked: 76 relevant articles (15 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Stasch, Johannes-Peter: 10 articles (09/2013 - 01/2009)
2. Ghofrani, Hossein-Ardeschir: 7 articles (11/2015 - 03/2010)
3. Frey, Reiner: 6 articles (11/2015 - 08/2008)
4. Hoeper, Marius M: 6 articles (06/2015 - 04/2013)
5. Grimminger, Friedrich: 6 articles (06/2015 - 03/2010)
6. Weimann, Gerrit: 5 articles (11/2015 - 08/2008)
7. Ghofrani, H A: 5 articles (03/2015 - 10/2008)
8. Mitrovic, Veselin: 4 articles (06/2015 - 03/2011)
9. Kretschmer, Axel: 4 articles (01/2013 - 01/2011)
10. Grimminger, F: 4 articles (10/2010 - 10/2008)

Related Diseases

1. Pulmonary Hypertension (Ayerza Syndrome)
2. Fibrosis (Cirrhosis)
08/01/2015 - "These data demonstrated potent antifibrotic effects of riociguat on experimental skin and organ fibrosis. "
08/01/2015 - "Riociguat dose-dependently reduced skin thickening, myofibroblast differentiation and accumulation of collagen with potent antifibrotic effects at 1 and 3 mg/kg. Riociguat also ameliorated fibrosis of the gastrointestinal tract in the cGvHD model. "
01/01/2013 - "These promising results suggest that sGC stimulators may constitute a valuable new therapy for PH. Other trials of riociguat are in progress, including a study of the haemodynamic effects and safety of riociguat in patients with PH associated with left ventricular diastolic dysfunction, and long-term extensions of the phase 3 trials investigating the efficacy and safety of riociguat in patients with PAH and chronic thromboembolic PH. Finally, sGC stimulators may also have potential therapeutic applications in other diseases, including heart failure, lung fibrosis, scleroderma and sickle cell disease. "
08/01/2010 - "In the 5/6 nephrectomy study part, riociguat reduced cardiac target organ damage as indicated by lower plasma ANP, lower relative left ventricular weight, lower myocyte diameter and lower arterial media/lumen ratio, and reduced renal target organ damage as indicated by improved creatinine clearance and less renal interstitial fibrosis. "
08/01/2015 - "Here, we aimed to demonstrate that riociguat, the drug candidate for clinical trials in systemic sclerosis (SSc), is effective in experimental fibrosis and to compare its efficacy to that of phosphodiesterase V inhibitors that also increase the intracellular levels of cyclic guanosine monophosphate. "
3. Hypertension (High Blood Pressure)
4. Heart Failure
5. Interstitial Lung Diseases (Interstitial Lung Disease)

Related Drugs and Biologics

1. Guanylate Cyclase (Guanylyl Cyclase)
2. Idiopathic pulmonary hypertension
3. Atrial Natriuretic Factor (ANF)
4. 5'-Guanylic Acid (GMP)
5. Type 5 Cyclic Nucleotide Phosphodiesterases
6. Creatinine
7. Renin
8. SU 5416 (SU5416)
9. NG-Nitroarginine Methyl Ester (L-NAME)
10. Urea (Carbamide)

Related Therapies and Procedures

1. Endarterectomy (Thromboendarterectomy)
2. Nephrectomy
3. Off-Label Use
4. Angioplasty (Angioplasty, Transluminal)
5. Therapeutics